Physician profile
Barry Statner
NPI 1740378728
$1,092.95
in general payments reported to CMS, 2019-2025
16 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2021: $156 · 2022: $253 · 2024: $95.62 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.33 | 2021-2025 | |
| Melinta Therapeutics, LLC | $144.69 | 2019-2022 | |
| Gilead Sciences, INC. | $134.97 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $100.53 | 2025 | Rebyota |
| Viiv Healthcare Company | $86.19 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $80.71 | 2019 | |
| Shionogi INC | $64.16 | 2022 | |
| Insmed, INC. | $62.51 | 2019-2024 | Arikayce |
| Allergan, INC. | $27.97 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $27.70 | 2024 | Vibativ |
| Grifols USA, LLC | $25.48 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $23.36 | 2019 | |
| Shire North American Group INC | $21.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.37 | 2025 | |
| Mayne Pharma Commercial LLC | $19.30 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.83 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Statner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.